LePure Biotech

Executive Summary

LePure Biotech is a Hangzhou-based biotechnology company specializing in the development and manufacturing of recombinant antibodies and proteins for therapeutic and diagnostic applications. Founded in 2010, the company operates as a platform, providing high-quality biologics as reagents and critical raw materials to the life science industry, while simultaneously advancing its own pipeline of diagnostic kits and therapeutic antibody candidates. With a focus on oncology and infectious diseases, LePure leverages its expertise in recombinant protein engineering to serve both as a supplier to the broader industry and as a developer of proprietary products. The company's dual revenue model—from reagent sales and potential therapeutic/diagnostic product sales—positions it to capture value across multiple segments of the biopharmaceutical value chain, though it remains privately held with limited public financial disclosure. Looking ahead, LePure's growth trajectory hinges on the successful progression of its proprietary therapeutic candidates and diagnostic products. The company's established manufacturing capabilities and long-standing presence in the biologics supply market provide a stable foundation, but near-term value creation likely depends on key clinical and regulatory milestones. With a workforce of 200–500 employees and a decade and a half of operational history, LePure is well-positioned to advance its pipeline, though competition in the biologics and diagnostics space remains intense. The following catalysts outline the most impactful near-term events expected to drive valuation.

Upcoming Catalysts (preview)

• Q3 2026Initiation of Phase I Clinical Trial for Lead Therapeutic Antibody (Oncology)60% success
• Q4 2026Regulatory Approval for a Proprietary Diagnostic Kit in China75% success
• Q2 2026Strategic Partnership or Licensing Deal for Manufacturing/Distribution65% success